Cancer BiologybioRxivPreprint
Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy
W. D. Mahauad-Fernandez, Y. C. Yang, I. Lai…·D. W. Felsher
This study identifies bi-steric mTORC1-selective inhibitors that reactivate 4EBP1, suppress MYC-driven tumors, and enhance immunotherapy in multiple cancer models.